Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $1.480
America/New_York / 31 mai 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 58.11 mill |
EPS: | -4.20 |
P/E: | -0.352 |
Earnings Date: | Aug 07, 2023 |
SharesOutstanding: | 39.26 mill |
Avg Daily Volume: | 0.325 mill |
RATING 2023-05-31 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.352 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.06x |
Company: PE -0.352 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.375 - 1.585 ( +/- 7.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-01 | Tang Kevin C | Sell | 4 394 800 | Common Stock |
2023-06-01 | Ubs Oncology Impact Fund L.p. | Sell | 3 370 982 | Common Stock |
2023-06-01 | Mpm Sunstates Fund, L.p. | Sell | 4 158 964 | Common Stock |
2023-06-01 | Mpm Bioventures 2014, L.p. | Sell | 4 158 964 | Common Stock |
2023-06-01 | Gadicke Ansbert | Sell | 3 370 982 | Common Stock |
INSIDER POWER |
---|
-89.42 |
Last 99 transactions |
Buy: 1 629 400 | Sell: 23 030 678 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.480 (0.00% ) |
Volume | 3.75 mill |
Avg. Vol. | 0.325 mill |
% of Avg. Vol | 1 154.74 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.